| アブストラクト | Background and Objective: Radium-223 dichloride (Xofigo(R)) is a calcium mimetic agent approved for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. This targeted, alpha-particle-emitting therapy has demonstrated significant survival benefit accompanied by a favorable safety profile. Nevertheless, recent evidence suggests that its combined use with abiraterone and prednisone/prednisolone may be associated with increased risk of death and fractures. While the precise pathophysiologic mechanisms of these events are not yet clear, collecting evidence from more clinical trials and translational studies is necessary. The aim of our present study is to assess whether accessible sources of patient outcome data can help gain additional clinical insights to radium-223 dichloride's safety profile. Materials and Methods: We performed a retrospective analysis of cases extracted from the FDA Adverse Event Reporting System and characterized side effect occurrence by using reporting ratios. Results: A total of ~1500 prostate cancer patients treated with radium-223 dichloride was identified, and side effects reported with the use of radium-223 dichloride alone or in combination with other therapeutic agents were extracted. Our analysis demonstrates that radium-223 dichloride may often come with hematological-related reactions, and that, when administered together with other drugs, its safety profile may differ. Conclusions: While more prospective studies are needed to fully characterize the toxicological profile of radium-223 dichloride, the present work constitutes perhaps the first effort to examine its safety when administered alone and in combination with other agents based on computational evidence from public real-world post marketing data. |
|---|
| ジャーナル名 | Medicina (Kaunas, Lithuania) |
|---|
| Pubmed追加日 | 2019/5/19 |
|---|
| 投稿者 | Soldatos, Theodoros G; Iakovou, Ioannis; Sachpekidis, Christos |
|---|
| 組織名 | Molecular Health GmbH, Heidelberg, Germany. soldatos@molecularhealth.com.;Department of Nuclear Medicine, Aristotle University of Thessaloniki,;Papageorgiou Hospital, Thessaloniki, Greece. soldatos@molecularhealth.com.;Department of Nuclear Medicine, Inselspital, Bern University Hospital, University;of Bern, Bern, Switzerland. soldatos@molecularhealth.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31100964/ |
|---|
